SCHEMBL7998596

SCHEMBL7998596

CC(C)CCCOc1ccccc1C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.63
ALDH1A1 P00352 6/20 0.63
KMT2A Q03164 3/20 0.63
PTK2B Q14289 1/20 0.63
KDM4E B2RXH2 6/20 0.61
HSD17B10 Q99714 3/20 0.61
PPIA P62937 1/20 0.52
MEN1 O00255 2/20 0.51
RECQL P46063 1/20 0.51
NPC1 O15118 1/20 0.51
CYP2C9 P11712 1/20 0.51
RAB9A P51151 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HPGD P15428 2/20 0.50
C5 P01031 1/20 0.50
LMNA P02545 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ESR1 P03372 1/20 0.49
ITGB3 P05106 1/20 0.49
ITGA2B P08514 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9410810 0.94 HTT (0.60) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL8850111 0.94 HTT (0.60) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL9410785 0.94 HTT (0.60) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL1735788 0.94 HTT (0.60) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL4611032 0.94 HTT (0.60) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL9954542 0.94 HTT (0.60) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL28919783 0.94 HTT (0.60) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL29829739 0.92 HTT (0.74) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL568543 0.92 HTT (0.74) HTTALDH1A1KMT2APTK2BKDM4E
SCHEMBL5172254 0.92 HTT (0.74) HTTALDH1A1KMT2APTK2BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0318941-A2 Developer for pressure-sensitive recording sheets, aqueous dispersion of the developer and method for preparing the developer Sanko Kaihatsu Kagaku Kenkyusho (JP) 1989-06-07 EP claimed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed
US-20230115176-A1 Complement Modulators and Related Methods RA PHARMACEUTICALS, INC. 2023-04-13 US disclosed
EP-3947352-A1 COMPLEMENT MODULATORS AND RELATED METHODS RA Pharmaceuticals, Inc. (US) 2022-02-09 EP disclosed
EP-0982621-B1 Film for optical elements NIPPON MITSUBISHI OIL CORP (JP) 2012-10-10 EP disclosed
US-6294229-B1 Film for optical elements NIPPON MITSUBISHI OIL COMPANY (JP) 2001-09-25 US disclosed
EP-0982621-A2 Film for optical elements Nippon Mitsubishi Oil Corporation (JP) 2000-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115176-A1 Complement Modulators and Related Methods C5, C9, C1QBP HTT 3241/4885ALDH1A1 4659/4885KMT2A 4703/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS HTT 1247/4885ALDH1A1 4236/4885KMT2A 4371/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS HTT 1247/4885ALDH1A1 4236/4885KMT2A 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.